CEP55 as a promising biomarker and therapeutic target on gallbladder cancer

Maotuan Huang; Maotuan Huang; Maotuan Huang; Maotuan Huang; Fuxiu Zhong; Fuxiu Zhong; Fuxiu Zhong; Mingyuan Chen; Mingyuan Chen; Mingyuan Chen; Mingyuan Chen; Lingju Hong; Lingju Hong; Lingju Hong; Lingju Hong; Weihong Chen; Weihong Chen; Weihong Chen; Weihong Chen; Xiahenazi Abudukeremu; Xiahenazi Abudukeremu; Xiahenazi Abudukeremu; Xiahenazi Abudukeremu; Feifei She; Feifei She; Yanling Chen; Yanling Chen; Yanling Chen; Yanling Chen

doi:10.3389/fonc.2023.1156177

Frontiers in Oncology (May 2023)

CEP55 as a promising biomarker and therapeutic target on gallbladder cancer

Maotuan Huang,
Maotuan Huang,
Maotuan Huang,
Maotuan Huang,
Fuxiu Zhong,
Fuxiu Zhong,
Fuxiu Zhong,
Mingyuan Chen,
Mingyuan Chen,
Mingyuan Chen,
Mingyuan Chen,
Lingju Hong,
Lingju Hong,
Lingju Hong,
Lingju Hong,
Weihong Chen,
Weihong Chen,
Weihong Chen,
Weihong Chen,
Xiahenazi Abudukeremu,
Xiahenazi Abudukeremu,
Xiahenazi Abudukeremu,
Xiahenazi Abudukeremu,
Feifei She,
Feifei She,
Yanling Chen,
Yanling Chen,
Yanling Chen,
Yanling Chen

Affiliations

Maotuan Huang: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Maotuan Huang: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Maotuan Huang: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Maotuan Huang: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Fuxiu Zhong: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Fuxiu Zhong: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Fuxiu Zhong: Department of Nursing, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Mingyuan Chen: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Mingyuan Chen: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Mingyuan Chen: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Mingyuan Chen: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Lingju Hong: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Lingju Hong: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Lingju Hong: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Lingju Hong: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Weihong Chen: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Weihong Chen: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Weihong Chen: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Weihong Chen: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Xiahenazi Abudukeremu: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Xiahenazi Abudukeremu: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Xiahenazi Abudukeremu: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Xiahenazi Abudukeremu: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Feifei She: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Feifei She: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China
Yanling Chen: Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China
Yanling Chen: Fujian Medical University Cancer Center, Fujian Medical University, Fuzhou, China
Yanling Chen: Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China
Yanling Chen: Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China

DOI: https://doi.org/10.3389/fonc.2023.1156177
Journal volume & issue: Vol. 13

Abstract

Read online

IntroductionGallbladder cancer (GBC) is a highly malignant biliary tumor with a poor prognosis. As existing therapies for advanced metastatic GBC are rarely effective, there is an urgent need to identify more effective targets for treatment.MethodsHub genes of GBC were identified by bioinformatics analysis and their expression in GBC was analyzed by tissue validation. The biological role of CEP55 in GBC cell and the underlying mechanism of the anticancer effect of CEP55 knockdown were evaluated via CCK8, colony formation assay, EDU staining, flow cytometry, western blot, immunofluorescence, and an alkaline comet assay.ResultsWe screened out five hub genes of GBC, namely PLK1, CEP55, FANCI, NEK2 and PTTG1. CEP55 is not only overexpressed in the GBC but also correlated with advanced TNM stage, differentiation grade and poorer survival. After CEP55 knockdown, the proliferation of GBC cells was inhibited with cell cycle arrest in G2/M phase and DNA damage. There was a marked increase in the apoptosis of GBC cells in the siCEP55 group. Besides, in vivo, CEP55 inhibition attenuated the growth and promoted apoptosis of GBC cells. Mechanically, the tumor suppressor effect of CEP55 knockdown is associated with dysregulation of the AKT and ERK signaling networks.DiscussionThese data not only demonstrate that CEP55 is identified as a potential independent predictor crucial to the diagnosis and prognosis of gallbladder cancer but also reveal the possibility for CEP55 to be used as a promising target in the treatment of GBC.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords